UBS Group’s Thorne Healthtech, Inc. Common Stock THRN Stock Holding History

UBS Group’s Portfolio THRN Stock Details THRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-124,779	Closed	-$1.27M	–	10525
2023 Q3	$1.27M	Buy	124,779 +116,685	+1,442%	+$888K	﹤0.01%	3872
2023 Q2	$38K	Buy	8,094 +3,309	+69%	+$15.2K	﹤0.01%	6613
2023 Q1	$22.1K	Buy	4,785 +2,637	+123%	+$11.6K	﹤0.01%	7007
2022 Q4	$7.8K	Buy	+2,148	New	+$9.52K	﹤0.01%	8856
2022 Q3	–	Sell	-1,652	Closed	-$8K	–	11312
2022 Q2	$8K	Sell	1,652 -304	-16%	-$1.85K	﹤0.01%	8404
2022 Q1	$12K	Sell	1,956 -3,758	-66%	-$20.2K	﹤0.01%	8232
2021 Q4	$35K	Buy	+5,714	New	+$44.7K	﹤0.01%	7241

UBS Group's THRN Position: Q4 2023 in Review

UBS Group sold out of Thorne Healthtech, Inc. Common Stock (THRN) in Q4 2023, closing a stake of 124,779 shares — an estimated $1.27M sold.

UBS Group first reported a position in THRN in Q4 2021 and held it in 7 quarters. The position peaked at $1.27M in Q3 2023. 0 funds tracked by Wall St. Rank hold THRN as of Q4 2023.

UBS Group reported no remaining Thorne Healthtech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
UBS Group sold 124,779 Thorne Healthtech, Inc. Common Stock shares in Q4 2023, an estimated $1.27M.
UBS Group first reported a position in Thorne Healthtech, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
UBS Group's Thorne Healthtech, Inc. Common Stock position peaked at $1.27M in Q3 2023.
0 funds tracked by Wall St. Rank held Thorne Healthtech, Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.